case
merscov
report
sinc
first
identifi
june
clinic
present
rang
asymptomat
mild
ill
rapidli
progress
diseas
multiorgan
failur
high
mortal
treatment
larg
support
larg
number
compound
shown
signific
vitro
inhibitori
activ
merscov
recent
macaqu
suitabl
anim
model
anim
studi
hinder
clinic
develop
merscov
therapi
howev
recent
success
develop
merscov
infect
model
transduc
mice
offer
opportun
acceler
clinic
develop
therapeut
agent
merscov
infect
current
avail
evid
support
clinic
investig
interferonbas
treatment
regimen
patient
merscov
combin
interferon
mycophenol
andor
highdos
ribavirin
appear
especi
promis
monoclon
antibodi
variou
target
within
merscov
spike
protein
yield
encourag
invitro
result
howev
safeti
efficaci
requir
confirm
anim
model
exploratori
clinic
trial
middl
east
respiratori
syndrom
coronaviru
merscov
first
identifi
patient
die
hospit
jeddah
saudi
arabia
june
sever
pneumonia
complic
multiorgan
failur
thereaft
retrospect
test
respiratori
serum
sampl
identifi
merscov
caus
hospitalbas
outbreak
undiagnos
respiratori
infect
zarga
jordan
april
april
global
total
case
merscov
infect
report
world
health
organ
major
infect
report
countri
arabian
peninsula
middl
east
includ
saudi
arabia
unit
arab
emir
qatar
oman
kuwait
yemen
jordan
egypt
lebanon
iran
case
also
report
countri
outsid
region
includ
uk
germani
franc
itali
greec
netherland
austria
turkey
tunisia
algeria
philippin
malaysia
usa
case
involv
individu
either
recent
arabian
peninsula
middl
east
someon
recent
contact
individu
merscov
infect
occur
commun
sporad
small
cluster
howev
larger
merscov
outbreak
mostli
associ
nosocomi
transmiss
mostli
result
high
rate
morbid
mortal
humantohuman
transmiss
well
document
howev
effect
infect
control
measur
implement
viru
potenti
caus
selfsustain
epidem
appear
low
present
dromedari
camel
emerg
import
host
merscov
merscov
neutral
antibodi
detect
dromedari
camel
saudi
arabia
oman
unit
arab
emir
jordan
even
egypt
eastern
africa
nigeria
tunisia
canari
island
primari
human
merscov
infect
never
report
moreov
merscov
genom
viabl
viru
isol
dromedari
camel
differ
part
arabian
peninsula
strongest
avail
evid
link
camel
human
merscov
infect
simultan
isol
nearli
ident
merscov
strain
camel
epidemiolog
link
human
case
saudi
arabia
qatar
merscov
commonli
detect
juvenil
older
camel
suggest
younger
dromedari
camel
may
particularli
import
role
viru
epidemiolog
interestingli
recent
publish
result
larg
nationwid
serosurvey
saudi
arabia
show
preval
merscov
antibodi
significantli
higher
individu
frequent
contact
anim
time
higher
shepherd
time
higher
slaughterhous
worker
compar
gener
popul
merscov
also
isol
singl
bat
saudi
arabia
moreov
close
relat
coronaviru
isol
bat
south
africa
phylogenet
analysi
latter
suggest
like
mani
human
coronavirus
merscov
ancestor
might
exist
old
world
bat
therefor
possibl
although
hitherto
unconfirm
epidemiolog
merscov
involv
bat
natur
reservoir
dromedari
camel
intermedi
cohost
clinic
spectrum
merscov
rang
complet
asymptomat
ill
rapidli
progress
fatal
diseas
major
hospit
patient
fever
cough
short
breath
radiolog
evid
lower
respiratori
tract
infect
gastrointestin
symptom
headach
gener
fatigu
also
common
respiratori
renal
organ
failur
frequent
complic
sever
merscov
infect
mani
patient
requir
admiss
intens
care
unit
although
overal
mortal
around
mortal
consider
higher
patient
sever
merscov
infect
support
care
mainstay
manag
patient
merscov
infect
howev
number
preclin
investig
therapeut
approach
describ
herein
review
potenti
therapeut
option
patient
merscov
infect
vitro
test
agent
alreadi
approv
antivir
clinic
indic
antimerscov
activ
obviou
advantag
establish
pharmacokinet
properti
safeti
profil
numer
agent
test
cell
cultur
sever
found
inhibitori
activ
merscov
tabl
interferon
product
signific
vitro
merscov
inhibitori
activ
howev
interferon
beta
potent
vitro
demonstr
vitro
activ
higher
interferon
higher
interferon
gamma
higher
interferon
even
interferon
gamma
show
use
vitro
merscov
inhibitori
activ
studi
note
merscov
time
sensit
vitro
interferon
alfa
sever
acut
respiratori
syndrom
coronaviru
sarscov
therefor
clinic
experi
gain
interferon
therapi
sar
outbreak
may
directli
applic
merscov
falzarano
et
al
assess
vitro
activ
interferon
alon
combin
ribavirin
use
vero
cell
line
note
compound
demonstr
use
antimerscov
activ
vero
cell
concentr
higher
achiev
clinic
tabl
howev
activ
sever
fold
higher
cell
vero
cell
known
rel
resist
ribavirin
observ
might
explain
consist
high
inhibitori
concentr
ic
valu
report
assay
util
cell
type
moreov
interferon
ribavirin
appli
combin
signific
synerg
observ
eightfold
reduct
ic
interferon
reduct
ribavirin
tabl
similar
synerg
previous
demonstr
interferon
plu
ribavirin
sarscov
mycophenol
acid
consist
demonstr
potent
vitro
merscov
inhibitori
activ
tabl
thought
exert
antivir
effect
modul
interferonstimul
gene
express
mycophenol
acid
wide
use
immun
suppress
agent
recipi
organ
transplant
clinic
indic
clinic
evalu
potenti
role
treatment
patient
merscov
infect
warrant
cyclosporin
appear
function
block
interact
viral
protein
cellular
cyclophilin
shown
prevent
merscov
cytopath
effect
prevent
cell
death
cell
cultur
howev
cell
continu
support
lowlevel
merscov
replic
rais
concern
possibl
emerg
resist
cyclosporin
clinic
treatment
antimerscov
compound
identifi
vitro
screen
larg
librari
use
cytopath
effect
assay
librari
fdaapprov
agent
test
vitro
merscov
activ
chloroquin
chlorpromazin
loperamid
lopinavir
found
inhibit
merscov
replic
low
concentr
lopinavir
previous
shown
inhibit
sarscov
replic
vitro
suggest
possibl
therapeut
option
merscov
howev
anoth
larg
vitro
studi
compound
screen
vitro
merscov
activ
mycophenol
acid
ribavirin
interferon
interferon
interferon
show
antimerscov
activ
lopinavir
nelfinavir
interferon
gamma
demonstr
suboptim
activ
dyall
et
al
use
cellbas
elisa
assay
screen
compound
either
fdaapprov
advanc
stage
develop
antimerscov
activ
sixti
agent
found
activ
merscov
includ
neurotransmitt
inhibitor
eg
chlorpromazin
triflupromazin
estrogen
receptor
antagonist
eg
tamoxifen
kinas
signal
inhibitor
eg
imatinib
dasatinib
inhibitor
lipid
sterol
metabol
eg
terconazol
triparanol
protein
process
inhibitor
eg
anisomycin
homoharringtonin
inhibitor
dna
synthesi
repair
eg
gemcitabin
antimalari
agent
eg
chloroquin
mefloquin
agent
describ
readili
avail
clinic
use
respect
licens
indic
although
optim
use
need
confirm
appropri
conduct
clinic
trial
may
use
offlabel
discret
physician
treat
patient
merscov
infect
merscov
carri
spike
protein
envelop
bind
specif
receptor
host
cell
dipeptidyl
peptidas
also
known
protein
compos
subunit
fig
protein
bind
receptorbind
domain
rbd
subunit
subunit
mediat
membran
fusion
includ
structur
two
heptad
repeat
domain
addit
fusion
protein
fp
transmembran
tm
cytoplasm
cd
domain
rbd
merscov
glycoprotein
induc
signific
neutral
antibodi
respons
monoclon
antibodi
design
produc
mice
immun
recombin
merscov
fuse
fc
block
merscov
entri
inhibit
cytopath
effect
cell
cultur
screen
larg
nonimmun
human
antibodi
librari
rbd
neutral
activ
result
identif
sever
potent
monoclon
antibodi
fig
exampl
three
highli
potent
human
monoclon
antibodi
neutral
pseudotyp
merscov
cell
cultur
ic
rang
potent
three
ic
inhibit
merscov
anoth
potenti
target
antimerscov
therapeut
adenosin
deaminas
natur
antagonist
shown
prevent
merscov
infect
cell
monoclon
antibodi
inhibit
bind
merscov
prevent
merscov
infect
cell
howev
express
epitheli
endotheli
cell
human
organ
involv
mani
import
function
includ
glucos
metabol
tcell
activ
chemotaxi
modul
cell
adhes
apoptosi
therefor
nonselect
inhibit
human
may
result
pleiotrop
effect
host
trigger
unexpect
advers
event
anoth
entri
mechan
merscov
membran
fusion
synthet
peptid
block
domain
merscov
protein
exhibit
potent
antivir
effect
vitro
fig
fusion
inhibitor
enfuvirtid
licens
treatment
patient
hiv
infect
peptid
merscov
analog
therefor
realist
potenti
option
merscov
therapi
requir
ex
vivo
vivo
assess
monoclon
antibodi
investig
peptid
promis
candid
evalu
except
high
neutral
activ
render
potenti
option
prevent
treatment
merscov
infect
nonimmun
antibodi
librari
thu
far
use
identifi
potent
merscov
human
monoclon
antibodi
would
great
interest
investig
sera
immun
individu
presenc
antibodi
well
screen
other
signific
neutral
activ
emphas
despit
potent
vitro
activ
safeti
efficaci
monoclon
antibodi
peptid
need
confirm
anim
model
follow
human
clinic
trial
potenti
concern
clinic
applic
monoclon
antibodi
merscov
therapi
emerg
escap
mutant
develop
resist
least
one
studi
escap
mutat
one
epitop
major
impact
neutral
antibodi
direct
epitop
may
prefer
merscov
monoclon
antibodi
use
combin
one
major
earlier
challeng
emerg
infecti
diseas
develop
success
anim
model
facilit
experiment
investig
understand
pathogenesi
identifi
potenti
therapeut
target
intervent
wildtyp
mice
support
merscov
target
bind
henc
viral
replic
lung
tissu
infect
evid
experiment
expos
mice
similarli
merscov
fail
replic
inocul
small
anim
ferret
syrian
hamster
howev
follow
intratrach
ocular
oral
intranas
inocul
infecti
dose
merscov
rhesu
macaqu
develop
clinic
sign
lower
respiratori
tract
infect
addit
compat
histolog
chang
evid
viru
replic
lung
tissu
gene
express
product
neutral
antibodi
cytokin
chemokin
product
follow
ex
vivo
demonstr
antivir
effect
interferon
ribavirin
merscov
falzarano
et
al
use
macaqu
studi
clinic
efficaci
combin
experiment
merscov
infect
two
set
three
rhesu
macaqu
infect
merscov
one
set
macaqu
commenc
h
infect
subcutan
interferon
million
unit
per
kg
everi
h
intramuscular
ribavirin
mg
per
kg
everi
h
anim
put
h
infect
unlik
treat
anim
untreat
macaqu
show
sign
respiratori
distress
decreas
oxygen
satur
develop
interstiti
infiltr
chest
radiograph
necropsi
show
lung
untreat
macaqu
firm
edemat
multifoc
consolid
wherea
treat
anim
normallook
lung
mean
viral
load
lung
tissu
treat
anim
significantli
lower
untreat
anim
moreov
treat
anim
show
reduc
system
local
product
proinflammatori
cytokin
indic
moder
host
respons
infect
find
provid
strong
support
potenti
role
earli
interferon
plu
ribavirin
therapi
merscov
infect
human
howev
administr
therapi
earli
h
human
infect
probabl
feasibl
clinic
set
one
remark
recent
develop
success
develop
experiment
merscov
infect
model
use
mice
transduc
recombin
nonrepl
adenoviru
express
receptor
investig
demonstr
transduc
balbc
mice
infect
merscov
fail
gain
weight
viral
replic
lung
tissu
patholog
evid
interstiti
pneumonia
furthermor
shown
mice
without
rigilik
receptor
rlr
tolllik
receptor
tlr
requir
interferon
induct
coronaviru
infect
sever
merscov
infect
delay
viral
clearanc
find
suggest
tlrdepend
ifn
signal
pathway
requir
merscov
control
investig
role
interferon
merscov
zhao
et
al
treat
adenoviru
mice
polyinosinicpolycytidyl
acid
poli
c
immunostimul
agonist
interferon
beta
interferon
gamma
inocul
merscov
poli
c
interferon
beta
therapi
result
acceler
viral
clearanc
without
increas
inflammatori
cell
infiltr
small
anim
model
reproduc
within
week
offer
great
potenti
acceler
experiment
work
elucid
detail
host
respons
involv
merscov
infect
investig
potenti
therapeut
intervent
includ
describ
clinic
data
merscov
therapi
remain
limit
case
report
case
seri
retrospect
cohort
studi
tabl
support
report
describ
effect
combin
interferon
ribavirin
vitro
macaqu
combin
wide
use
earliest
clinic
report
emerg
eastern
provinc
saudi
arabia
five
patient
sever
merscov
infect
start
highdos
ribavirin
plu
interferon
median
day
hospit
patient
critic
ill
signific
comorbid
none
patient
surviv
largest
studi
date
includ
patient
sever
merscov
infect
requir
respiratori
support
twenti
patient
receiv
interferon
plu
highdos
ribavirin
median
day
diagnosi
compar
histor
match
cohort
patient
combin
therapi
associ
significantli
improv
surviv
diagnosi
vs
strong
trend
toward
improv
surviv
combin
group
differ
statist
signific
vs
similarli
recent
report
singl
center
jeddah
saudi
arabia
overal
inhospit
mortal
patient
sever
merscov
infect
despit
receiv
ribavirin
plu
either
interferon
interferon
within
median
day
diagnosi
mortal
significantli
differ
patient
receiv
interferon
alfa
compar
patient
receiv
interferon
beta
therapi
sampl
size
studi
probabl
inadequ
demonstr
improv
longterm
surviv
especi
merscov
patient
signific
comorbid
cours
merscov
infect
frequent
complic
hospitalacquir
infect
like
contribut
patient
poor
outcom
furthermor
treatment
studi
start
patient
alreadi
ill
requir
respiratori
support
contrast
macaqu
studi
treatment
commenc
within
h
experiment
infect
interestingli
initi
treatment
patient
mild
symptom
radiolog
evid
pneumonia
associ
full
recoveri
whether
initi
combin
therapi
earlier
cours
merscov
ill
benefici
question
address
appropri
design
power
clinic
trial
case
report
greec
describ
one
patient
merscov
infect
die
despit
tripl
therapi
interferon
ribavirin
lopinavir
patient
multiorgan
failur
later
diagnos
colon
cancer
merscov
detect
respiratori
tract
sever
day
death
neither
two
report
patient
cyclosporin
prior
merscov
infect
indic
surviv
one
renal
transplant
recipi
mycophenol
prednisolon
surviv
merscov
infect
howev
requir
ventil
support
receiv
antivir
therapi
publish
report
therapeut
use
mycophenol
cyclosporin
chloroquin
agent
shown
antimerscov
activ
vitro
tabl
recent
avail
merscov
infect
model
transduc
mice
provid
much
need
opportun
acceler
clinic
develop
variou
compound
potent
vitro
merscov
inhibitori
activ
evid
avail
far
support
clinic
investig
interferon
beta
lesser
extent
interferon
alfa
base
treatment
regimen
patient
merscov
combin
interferon
mycophenol
andor
high
dose
ribavirin
noninfecti
complic
includ
congest
heart
failur
acut
myocardi
infarct
pulmonari
embol
intracrani
hemorrhag
final
outcom
die
braindead
recov
aki
acut
kidney
injuri
apach
ii
acut
physiolog
chronic
health
evalu
ii
ard
acut
respiratori
distress
syndrom
atvr
atazanavirritonavir
crrt
continu
renal
replac
therapi
ftc
emtricitabin
icu
intens
care
unit
inf
interferon
mv
mechan
ventil
peginf
pegyl
interferon
rtpcr
realtim
polymeras
chain
reaction
rbv
ribavirin
sd
standard
deviat
tdf
tenofovir
dipivoxil
fumer
appear
especi
promis
role
monoclon
antibodybas
merscov
therapi
warrant
addit
investig
anim
model
small
exploratori
clinic
trial
establish
safeti
import
clinic
efficaci
conflict
interest
ali
omrani
ziad
memish
declar
compet
interest
articl
contain
studi
human
anim
subject
perform
author
